REVIEW
SA JOURNAL OF DIABETES & VASCULAR DISEASE
32
VOLUME 11 NUMBER 1 • MARCH 2014
43. Gutzwiller JP, Tschopp S, Bock A
et al
. Glucagon-like peptide 1 induces natriuresis
in healthy subjects and in insulin-resistant obese men.
J Clin Endocrinol Metab
2004;
89
: 3055–3061.
44. Tanaka T, Nangaku M and Nishiyama A. The role of incretins in salt-sensitive
hypertension: The potential use of dipeptidyl peptidase-IV inhibitors.
Curr Opin
Nephrol Hypertens
2011;
20
: 476–481.
45. Ishibashi Y, Matsui T, Takeuchi M
et al
. Glucagon-like peptide-1 (GLP-1) inhibits
advanced glycation end product (AGE)-induced up-regulation of VCAM-1
mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression.
Biochem Biophys Res Commun
2010;
391
: 1405–1408.
46. Kodera R, Shikata K, Kataoka HU
et al
. Glucagon-like peptide-1 receptor agonist
ameliorates renal injury through its anti-inflammatory action without lowering
blood glucose level in a rat model of Type 1 diabetes.
Diabetologia
2011;
54
:
965–978.
47. Delgado-Aros S, Kim DY, Burton DD
et al.
Effect of GLP-1 on gastric volume,
emptying, maximum volume ingested, and postprandial symptoms in humans.
Am J Physiol Gastrointest Liver Physiol
2002;
282
: G424–431.
48. Marathe CS, Rayner CK, Jones KL
et al
. Effects of GLP-1 and incretin-based
therapies on gastrointestinal motor function.
Exp Diabetes Res
2011; 2011:
279530.
49. Drucker DJ, Buse JB, Taylor K
et al
. Exenatide once weekly versus twice daily
for the treatment of Type 2 diabetes: A randomised, open-label, non-inferiority
study.
Lancet
2008;
372
: 1240–1250.
50. Marre M, Shaw J, Brändle M
et al
. Liraglutide, a oncedaily human GLP-1 analogue,
added to a sulphonylurea over 26 weeks produces greater improvements in
glycaemic and weight control compared with adding rosiglitazone or placebo in
subjects with Type 2 diabetes (LEAD-1 SU).
Diabet Med
2009;
26
: 268–278.
51. Cohen D. Reports of pancreatitis are 20–30 times more likely with GLP-1 drugs,
analysis finds.
Br Med J
2013;
346
: f2607.
52. Barnett AH and O’Hare P. Cardiovascular benefits of incretins.
Br Med J
2013;
347
: f4382.
53. Holt RI. The BMJ and Dispatches gave only one side of the story.
Br Med J
2013;
347
: f4379.
54. Elashoff M, Matveyenko AV, Gier B
et al
. Pancreatitis, pancreatic, and thyroid
cancer with glucagon-like peptide-1-based therapies.
Gastroenterology
2011;
141
: 150–156.
55. Singh S, Chang HY, Richards TM
et al.
Glucagon-like peptide 1-based therapies
and risk of hospitalization for acute pancreatitis in Type 2 diabetes mellitus: A
population-based matched case-control study.
J Am Med Assoc Intern Med
2013;
173
: 534–539.
56. Engel SS, Round E, Golm GT
et al
. Safety and tolerability of sitagliptin in Type 2
diabetes: pooled analysis of 25 clinical studies.
Diabetes Ther
2013;
4
: 119–145.
57. Monami M, Dicembrini I and Mannucci E. Dipeptidyl peptidase-4 inhibitors and
pancreatitis risk: A meta-analysis of randomized clinical trials.
Diabetes Obes
Metab
2013; Jul: doi:
10
.1111/dom.12176.
58. Alves C, Batel-Marques F and Macedo AF. A meta-analysis of serious adverse
events reported with exenatide and liraglutide: Acute pancreatitis and cancer.
Diabetes Res Clin Pract
2012;
98
: 271–284.
59. Shyangdan DS, Royle P, Clar C
et al
. Glucagon-like peptide analogues for Type 2
diabetes mellitus.
Cochrane Database Syst Rev
2011: CD006423.
60. Busch SJ, Hoffmann P, Sahota P
et al.
Studies in rodents with the dipeptidyl
peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic
histological changes that are predictive of pancreatitis and cancer development
in man.
Diabetes Obes Metab
2013;
15
: 72–76.
61. Gier B, Matveyenko AV, Kirakossian D
et al
. Chronic GLP-1 receptor activation
by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates
formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse
model.
Diabetes
2012;
61
: 1250–1262.
62. Butler AE, Campbell-Thompson M, Gurlo T
et al
. Marked expansion of exocrine
and endocrine pancreas with incretin therapy in humans with increased exocrine
pancreas dysplasia and the potential for glucagon-producing neuroendocrine
tumours.
Diabetes
2013;
62
: 2595–2604.
63. Romley JA, Goldman DP, Solomon M
et al
. Exenatide therapy and the risk of
pancreatitis and pancreatic cancer in a privately insured population.
Diabetes
Technol Ther
2012;
14
: 904–911.
64. Tourrel C, Bailbé D, Meile MJ
et al
. Glucagon-like peptide-1 and exendin-4
stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting
in persistently improved glucose homeostasis at adult age.
Diabetes
2001;
50
:
1562–1570.
65. Shimoda M, Kanda Y, Hamamoto S
et al.
The human glucagon-like peptide-1
analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics
and suppression of oxidative and endoplasmic reticulum stress in a mouse model
of diabetes.
Diabetologia
2011;
54
: 1098–1108.
66. Preumont V, Hermans MP, Brichard S
et al
. Six-month exenatide improves HOMA
hyperbolic product in Type 2 diabetic patients mostly by enhancing beta-cell
function rather than insulin sensitivity.
Diabetes Metab
2010;
36
: 293–298.
67. Bjerre Knudsen L, Madsen LW, Andersen S
et al
. Glucagon-like Peptide-1 receptor
agonists activate rodent thyroid C-cells causing calcitonin release and C-cell
proliferation.
Endocrinology
2010;
151
: 1473–1486.
68. Hegedüs L, Moses AC, Zdravkovic M
et al
. GLP-1 and calcitonin concentration
in humans: Lack of evidence of calcitonin release from sequential screening in
over 5000 subjects with Type 2 diabetes or nondiabetic obese subjects treated
with the human GLP-1 analog, liraglutide.
J Clin Endocrinol Metab
2011;
96
:
853–860.
69. Bunck MC, Cornér A, Eliasson B
et al.
One-year treatment with exenatide vs.
insulin glargine: Effects on postprandial glycemia, lipid profiles, and oxidative
stress.
Atherosclerosis
2010;
212
: 223–229.
70. Varanasi A, Chaudhuri A, Dhindsa S
et al
. Durability of effects of exenatide
treatment on glycemic control, body weight, systolic blood pressure, C-reactive
protein, and triglyceride concentrations.
Endocr Pract
2011;
17
: 192–200.
71. Meier JJ, Gethmann A, Götze O
et al
. Glucagon-like peptide 1 abolishes the
postprandial rise in triglyceride concentrations and lowers levels of non-esterified
fatty acids in humans.
Diabetologia
2006;
49
: 452–458.
72. Horowitz M, Flint A, Jones KL
et al
. Effect of the oncedaily human GLP-1 analogue
liraglutide on appetite, energy intake, energy expenditure and gastric emptying in
Type 2 diabetes.
Diabetes Res Clin Pract
2012;
97
: 258–266.
73. Harder H, Nielsen L, Tu DT
et al
. The effect of liraglutide, a long-acting glucagon-
like peptide-1 derivative, on glycemic control, body composition, and 24-h
energy expenditure in patients with Type 2 diabetes.
Diabetes Care
2004;
27
:
1915–1921.
74. Flint A, Raben A, Rehfeld JF
et al
. The effect of glucagon-like peptide-1 on energy
expenditure and substrate metabolism in humans.
Int J Obes Relat Metab Disord
2000;
24
: 288–298.
75. Inoue K, Maeda N, Kashine S
et al
. Short-term effects of liraglutide on visceral
fat adiposity, appetite, and food preference: A pilot study of obese Japanese
patients with Type 2 diabetes.
Cardiovasc Diabetol
2011;
10
: 109. Online only.
DOI: 10.1186/1475-2840-10-109.
76. Jendle J, Nauck MA, Matthews DR
et al
. Weight loss with liraglutide, a once-
daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as
monotherapy or added to metformin, is primarily as a result of a reduction in fat
tissue.
Diabetes Obes Metab
2009;
11
: 1163–1172.
77. Lee CM, Huxley RR, Wildman RP
et al
. Indices of abdominal obesity are better
discriminators of cardiovascular risk factors than BMI: A meta-analysis.
J Clin
Epidemiol
2008;
61
: 646–653.
78. Ghiglione M, Uttenthal LO, George SK
et al.
How glucagon- like is glucagon-like
peptide-1?
Diabetologia
1984;
27
: 599–600.
